Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Hypertension Market to Accelerate Positively, Estimates DelveInsight | Key Companies Active in the Market - Novartis, Bayer, Merck, Insmed, Acceleron, AbbVie, Alnylam, Apnimed, AstraZeneca, Gossamer Bio

      DelveInsight_Logo

      News provided by

      DelveInsight Business Research, LLP

      Jul 19, 2023, 17:01 ET

      Share this article

      Share this article


      According to DelveInsight, the hypertension market in the 7MM is expected to significantly change during the study period 2019–2032. While the hypertension market has generally shown a positive trend, certain factors could potentially contribute to a decline involving low compliance with antihypertensives or poor access to newer medications.

      LAS VEGAS, July 19, 2023 /PRNewswire/ -- DelveInsight's Hypertension Market Insights report includes a comprehensive understanding of current treatment practices, hypertension emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

      Key Takeaways from the Hypertension Market Report

      • As per DelveInsight analysis, the hypertension market is expected to grow positively at a significant CAGR during the study period (2019–2032).
      • According to World Health Organization (2023), the prevalence of hypertension shows regional and income group variations, with the WHO Region of the Americas exhibiting the lowest prevalence of hypertension at 18%. Different regions and countries display varying rates of hypertension.
      • Leading hypertension companies such as JeniVision, Inc., AI Therapeutics, Inc., Apnimed, AstraZeneca, Aerovate Therapeutics, Merck Sharp & Dohme LLC, AbbVie, Alnylam Pharmaceuticals, Gossamer Bio Inc., Insmed Incorporated, Actelion, Boehringer Ingelheim, Acceleron Pharma, Bayer, Perfuse Therapeutics, Inc., KBP Biosciences, Novartis, Gmax Biopharm LLC, United Therapeutics, Tarsier Pharma, and others are developing novel hypertension drugs that can be available in the hypertension market in the coming years.
      • Some key therapies for hypertension treatment include JV-GL1, LAM-001, AD113, AZD3427, AV-101, CIN-107, MK-5475, AGN-193408 SR, ALN-AGT01, GB002, Treprostinil Palmitil, Macitentan, BI 685509, Sotatercept, BAY63-2521, PER-001, KBP-5074, LTP001, Q4W GMA301 IV injections, Ralinepag, TRS01, and others.

      Discover which therapies are expected to grab the major hypertension market share @ Hypertension Market Report

      Hypertension Overview

      Hypertension, often known as high blood pressure, is a common medical condition marked by consistently high blood pressure readings. Primary hypertension and secondary hypertension are the two common types of hypertension. The most common type of hypertension has multiple causes, including genetics, lifestyle factors, and aging. Secondary hypertension is caused by an underlying medical problem. Elevated, Stage 1, Stage 2, and hypertensive crisis are the major classifications for the condition.

      Hypertension is diagnosed by monitoring a person's blood pressure to see if it is above the usual range. To acquire reliable readings, a healthcare worker often uses a blood pressure cuff, sphygmomanometer, or automated blood pressure monitoring device. Diagnosis of hypertension is difficult due to its silent nature, with no obvious symptoms in the early stages, which leads to underdiagnosis.

      Hypertension Epidemiology Segmentation

      The hypertension epidemiology section provides insights into the historical and current hypertension patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.  

      The hypertension market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

      • Hypertension Diagnosed Prevalent Cases
      • Hypertension Gender-specific Diagnosed Prevalent Cases
      • Hypertension Age-specific Diagnosed Prevalent Cases
      • Hypertension Severity-specific Diagnosed Prevalent Cases

      Hypertension Treatment Market 

      Hypertension is often treated with a combination of lifestyle changes and medication. Adopting a low-sodium, nutritious diet, engaging in regular physical activity, keeping a healthy weight, limiting alcohol consumption, and quitting smoking are all examples of lifestyle modifications. Blood pressure medications such as diuretics, beta-blockers, ACE inhibitors, ARBs, and calcium channel blockers can be administered. Individuals with hypertension can effectively control their illness and reduce the risk of consequences by using these measures. Adherence to lifestyle changes and medicine might be difficult due to a variety of issues such as time constraints, a lack of enthusiasm, and the patient's forgetful disposition.

      In addition to lifestyle modifications and medication, hypertension treatment may also involve addressing underlying health conditions that contribute to high blood pressure. For instance, if hypertension is caused by an underlying condition such as kidney disease or hormonal disorders, treating or managing these conditions becomes an integral part of the overall treatment plan. Furthermore, patient education and self-care play crucial roles in hypertension treatment. Individuals with high blood pressure are often advised to monitor their blood pressure at home using home blood pressure monitors and to keep track of their readings. This empowers patients to actively participate in their own care and enables them to recognize any abnormal patterns or fluctuations in blood pressure.

      To know more about hypertension treatment, visit @ Hypertension Treatment Drugs 

      Key Hypertension Therapies and Companies

      • JV-GL1: JeniVision, Inc.
      • LAM-001: AI Therapeutics, Inc.
      • AD113: Apnimed
      • AZD3427: AstraZeneca
      • AV-101:Aerovate Therapeutics
      • CIN-107: AstraZeneca
      • MK-5475: Merck Sharp & Dohme LLC
      • AGN-193408 SR: AbbVie
      • ALN-AGT01: Alnylam Pharmaceuticals
      • GB002: Gossamer Bio Inc.
      • Treprostinil Palmitil: Insmed Incorporated
      • Macitentan: Actelion
      • BI 685509: Boehringer Ingelheim
      • Sotatercept: Acceleron Pharma
      • BAY63-2521: Bayer
      • PER-001: Perfuse Therapeutics, Inc.
      • KBP-5074: KBP Biosciences
      • LTP001: Novartis
      • Q4W GMA301 IV injections: Gmax Biopharm LLC
      • Ralinepag: United Therapeutics
      • TRS01: Tarsier Pharma

      Learn more about the FDA-approved drugs for hypertension @ Drugs for Hypertension Treatment 

      Hypertension Market Dynamics

      The dynamics of the hypertension market are expected to change in the coming years. The rising prevalence of the disease is the prominent factor boosting the growth of the hypertension market. In addition, the increase in healthcare spending and rising R&D activities are also likely to propel the hypertension market in the next few years. Furthermore, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the hypertension market in the 7MM.

      However, several factors are impeding the growth of the hypertension market. The hypertension market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the hypertension market growth.

       

      Report Metrics

      Details

      Study Period

      2019–2032

      Coverage

      7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

      Key Hypertension Companies

      JeniVision, Inc., AI Therapeutics, Inc., Apnimed, AstraZeneca, Aerovate Therapeutics, Merck Sharp & Dohme LLC, AbbVie, Alnylam Pharmaceuticals, Gossamer Bio Inc., Insmed Incorporated, Actelion, Boehringer Ingelheim, Acceleron Pharma, Bayer, Perfuse Therapeutics, Inc., KBP Biosciences, Novartis, Gmax Biopharm LLC, United Therapeutics, Tarsier Pharma, and others

      Key Hypertension Therapies

      JV-GL1, LAM-001, AD113, AZD3427, AV-101, CIN-107, MK-5475, AGN-193408 SR, ALN-AGT01, GB002, Treprostinil Palmitil, Macitentan, BI 685509, Sotatercept, BAY63-2521, PER-001, KBP-5074, LTP001, Q4W GMA301 IV injections, Ralinepag, TRS01, and others

      Scope of the Hypertension Market Report

      • Therapeutic Assessment: Hypertension current marketed and emerging therapies
      • Hypertension Market Dynamics: Conjoint Analysis of Emerging Hypertension Drugs
      • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
      • Unmet Needs, KOL's views, Analyst's views, Hypertension Market Access and Reimbursement

      Discover more about hypertension drugs in development @ Hypertension Clinical Trials

      Table of Contents

       

      1.

      Hypertension Market Key Insights

      2.

      Hypertension Market Report Introduction

      3.

      Hypertension Market Overview at a Glance

      4.

      Hypertension Market Executive Summary

      5.

      Disease Background and Overview

      6.

      Hypertension Treatment and Management

      7.

      Hypertension Epidemiology and Patient Population

      8.

      Patient Journey

      9.

      Hypertension Marketed Drugs

      10.

      Hypertension Emerging Drugs

      11.

      Seven Major Hypertension Market Analysis

      12.

      Hypertension Market Outlook

      13.

      Potential of Current and Emerging Therapies

      14.

      KOL Views

      15.

      Unmet Needs

      16.

      SWOT Analysis

      17.

      Appendix

      18.

      DelveInsight Capabilities

      19.

      Disclaimer

      20.

      About DelveInsight

      Related Reports

      Hypertension Pipeline

      Hypertension Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hypertension companies, including Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis, Cereno Scientific AB, Torrent Pharmaceuticals Limited, JeniVision, Inc., Merck Sharp & Dohme LLC, AbbVie, Acceleron Pharma Inc., Hanmi Pharmaceutical Company Limited, Gossamer Bio Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Insmed Incorporated, Gmax Biopharm LLC., Altavant Sciences GmbH, Bayer, Respira Therapeutics, Inc., Aadi Bioscience, Inc., Boehringer Ingelheim, JW Pharmaceutical, PRM Pharma, LLC, PolyActiva Pty Ltd, pH Pharma, Nicox Ophthalmics, Inc., Ocular Therapeutix, Inc., Santen SAS, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, AJU Pharm Co., Ltd., Laboratoires Thea, Aerami Therapeutics, KBP Biosciences, Cumberland Pharmaceuticals, Vigonvita Life Sciences, IlDong Pharmaceutical Co Ltd, Qlaris Bio, Inc., Santen Pharmaceutical,  VivaVision Biotech, Mitsubishi Chemical Group Corporation., Idorsia Pharmaceuticals, United Therapeutics Corporation, VIVUS LLC., PhaseBio Pharmaceuticals, Vascular Biosciences, CAR peptide, Liquidia Corporation, Centessa Pharmaceuticals, Claritas Pharmaceuticals, Halo Biosciences, PulmoSIM Therapeutics, Keros Therapeutics, among others.

      Pulmonary Hypertension Pipeline

      Pulmonary Hypertension Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pulmonary arterial hypertension companies, including Reata Pharmaceuticals, Pharmosa BioPharm, United Therapeutics Corporation, Acceleron Pharma, Bellerophon Therapeutics, Dong-A ST, Mezzion, Northern Therapeutics, Merck Sharp & Dohme Corp., Apeiron Biologics, VIVUS, Respira Therapeutics, Resverlogix, Bial - Portela C S.A., Vigonvita Life Sciences, Altavant Sciences, Roche, PhaseBio Pharmaceuticals, Gossamer Bio, Reviva Biopharmaceuticals, Cereno Scientific, Attgeno, Rho Federal Systems Division, Inc., Cumberland Pharmaceuticals, AstraZeneca, Aerovate Therapeutics, Celon Pharma, Camurus, ATXA Therapeutics, Gmax Biopharma, Aerami Therapeutics, Pfizer, Aadi Biosciences, SystImmune, Claritas Pharmaceuticals, Reviva Biopharmaceuticals, Aqualung Therapeutics, Pulmokine, Recursion Pharmaceuticals, among others.

      Pulmonary Arterial Hypertension Pipeline

      Pulmonary Arterial Hypertension Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pulmonary arterial hypertension companies, including Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic, among others.

      Pulmonary Arterial Hypertension Market

      Pulmonary Arterial Hypertension Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pulmonary arterial hypertension companies including Merck, United Therapeutics, Liquida Technologies, Tenax Therapeutics, Respira Therapeutics, Gossamer Bio, Pharmosa Biopharma, Aerovate Therapeutics, Insmed, Novartis, Cumberland Pharmaceuticals, Enzyvant Therapeutics, AstraZeneca, Cereno Scientific, PhaseBio Pharmaceutical, among others.

      About DelveInsight

      DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

      Contact Us

      Shruti Thakur
      [email protected]  
      +1(919)321-6187
      www.delveinsight.com 

       Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

      SOURCE DelveInsight Business Research, LLP

      Modal title

      Also from this source

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Recently published Epilepsy Market Insights report includes a comprehensive understanding of current treatment practices, epilepsy emerging drugs,...

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      DelveInsight's JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.